Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the commencement of an underwritten public offering valued at $200 million. The offering includes shares of its common stock and pre-funded warrants for those investors opting for them instead of the common stock. Additionally, Enliven may grant underwriters a 30-day option to purchase up to an extra $30 million in common stock. The offering is contingent on market conditions, with no assurance of completion or specific terms. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are serving as joint book-running managers, and LifeSci Capital is acting as lead manager for the offering.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。